Zanubrutinib Appears to be Safe, Effective for Waldenstr öm Macroglobulinemia
According to the largest phase III trial examining BTK inhibitors for patients with Waldenstr öm macroglobulinemia, zanubrutinib appears to be associated with higher complete response or very good partial response, as well as clinically meaningful advantages in safety and tolerability compared to ibrutinib.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news